$417 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XENE | Buy | XENON PHARMACEUTICALS INC | $33,594,000 | +19.4% | 1,104,334 | +20.0% | 8.06% | +18.5% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $29,642,000 | +22.8% | 190,000 | +22.6% | 7.11% | +21.9% |
| CYTK | Sell | CYTOKINETICS INC | $23,967,000 | +0.2% | 610,000 | -6.2% | 5.75% | -0.6% |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $23,533,000 | -9.6% | 971,233 | -3.8% | 5.64% | -10.3% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCput | $21,878,000 | – | 150,000 | +100.0% | 5.25% | – |
| PCVX | Buy | VAXCYTE INC | $21,437,000 | +0.3% | 985,153 | +11.3% | 5.14% | -0.5% |
| GLPG | GALAPAGOS NVspon adr | $20,088,000 | -10.0% | 360,000 | 0.0% | 4.82% | -10.7% | |
| KRTX | New | KARUNA THERAPEUTICS INC | $18,850,000 | – | 149,000 | +100.0% | 4.52% | – |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $16,484,000 | +0.4% | 2,420,501 | +17.5% | 3.95% | -0.4% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $15,119,000 | -6.9% | 1,083,000 | +14.9% | 3.63% | -7.7% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $15,055,000 | +16.8% | 1,530,000 | +75.0% | 3.61% | +16.0% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $14,535,000 | – | 193,900 | +100.0% | 3.49% | – |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $13,293,000 | -37.7% | 700,000 | -11.4% | 3.19% | -38.1% |
| Buy | CINCOR PHARMA INC | $12,608,000 | +802.5% | 669,200 | +740.0% | 3.02% | +794.7% | |
| NKTR | New | NEKTAR THERAPEUTICS | $11,970,000 | – | 3,150,000 | +100.0% | 2.87% | – |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $11,667,000 | +5.0% | 1,204,028 | +7.7% | 2.80% | +4.2% |
| TCDA | Sell | TRICIDA INC | $11,275,000 | +9.7% | 1,164,763 | -6.8% | 2.70% | +8.9% |
| ALKS | New | ALKERMES PLC | $10,773,000 | – | 361,636 | +100.0% | 2.58% | – |
| DTIL | New | PRECISION BIOSCIENCES INC | $9,209,000 | – | 5,755,396 | +100.0% | 2.21% | – |
| ANAB | Sell | ANAPTYSBIO INC | $9,198,000 | -46.9% | 453,118 | -35.3% | 2.21% | -47.3% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $7,311,000 | – | 75,000 | +100.0% | 1.75% | – |
| RNA | AVIDITY BIOSCIENCES INC | $7,265,000 | -21.3% | 500,000 | 0.0% | 1.74% | -22.0% | |
| URGN | UROGEN PHARMA LTD | $7,153,000 | -6.0% | 873,424 | 0.0% | 1.72% | -6.7% | |
| ABOS | Buy | ACUMEN PHARMACEUTICALS INC | $7,121,000 | +96.2% | 1,515,000 | +63.2% | 1.71% | +94.8% |
| KRTX | New | KARUNA THERAPEUTICS INCput | $6,945,000 | – | 54,900 | +100.0% | 1.67% | – |
| KDNY | Sell | CHINOOK THERAPEUTICS INC | $5,889,000 | -74.7% | 336,731 | -76.3% | 1.41% | -74.9% |
| Buy | VENTYX BIOSCIENCES INC | $4,760,000 | +4.3% | 389,223 | +15.7% | 1.14% | +3.5% | |
| SLN | Sell | SILENCE THERAPEUTICS PLCads | $4,757,000 | -43.7% | 401,449 | -9.7% | 1.14% | -44.1% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $4,698,000 | -29.5% | 2,512,500 | +14.3% | 1.13% | -30.0% |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $4,585,000 | – | 538,819 | +100.0% | 1.10% | – |
| ETNB | New | 89BIO INC | $4,508,000 | – | 1,400,000 | +100.0% | 1.08% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $2,862,000 | – | 357,263 | +100.0% | 0.69% | – |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $2,268,000 | – | 432,000 | +100.0% | 0.54% | – | |
| MGTA | MAGENTA THERAPEUTICS INC | $1,404,000 | -58.6% | 1,170,000 | 0.0% | 0.34% | -58.9% | |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $1,263,000 | – | 2,500,000 | +100.0% | 0.30% | – |
| RFL | Exit | RAFAEL HLDGS INC | $0 | – | -121,000 | -100.0% | -0.07% | – |
| PASG | Exit | PASSAGE BIO INC | $0 | – | -113,900 | -100.0% | -0.08% | – |
| NKTR | Exit | NEKTAR THERAPEUTICScall | $0 | – | -100,000 | -100.0% | -0.13% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -4,761,905 | -100.0% | -1.23% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -4,000,000 | -100.0% | -2.89% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -5.36% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -550,592 | -100.0% | -5.84% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -1,300,000 | -100.0% | -7.12% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.